{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 72 of 169', 'part of the eDiary each day in the morning from Week -2 (visit 2) until Week 52. The PGI-S is', 'included in the investigator trial file.', '10.3.2.6 Patient-Oriented Eczema Measure', 'The Patient-Oriented Eczema Measure (POEM) is a validated questionnaire used to assess', 'disease symptoms in atopic eczema patients in both clinical practice and clinical trials (21).', 'The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding,', 'weeping, cracking, flaking, and dryness). Subject will score how often they have experienced', \"each symptom over the previous week on a 5-point categorical response scale (0 = 'no days';\", \"1 = 1 to 2 days'; 2 = '3 to 4 days'; 3 = '5 to 6' days; 4 = 'every day'). The total score is the\", 'sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is', 'indicative of a worse disease severity. The POEM will be completed according to the SoP in', 'Section 4. It will be completed electronically on the device supplied to the trial site and is', 'included in the investigator trial file.', '10.3.2.7 Dermatology Life Quality Index', 'The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content', \"specific to those with dermatology conditions. It consists of 10 items addressing the subject's\", 'perception of the impact of their skin disease on different aspects of their HQoL over the last', 'week such as dermatology-related symptoms and feelings, daily activities, leisure, work or', 'school, personal relationships, and the treatment (22). Each item is scored on a 4-point Likert', \"scale (0 = 'not at all/not relevant'; 1 = 'a little'; 2 = 'a lot'; 3 = 'very much'). The total score\", 'is the sum of the 10 items (0 to 30); a high score is indicative of a poor HQoL. The DLQI will', 'be completed according to the SoP in Section 4. It will be completed electronically on the', 'device supplied to the trial site and is included in the investigator trial file.', '10.3.2.8 EQ-5D-5L', 'The EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) is a standardised', 'measure of health status developed by the EuroQol group to provide a simple, generic', 'measure of health for clinical and economic appraisal (23). The EQ-5D-5L is a', 'self-administered questionnaire used to assess health status \"today\\' and is divided into', '2 sections: The first section includes 5 dimensions (mobility, self-care, usual activity,', 'pain/discomfort, and anxiety/depression); each dimension will be assessed by the subject', 'using a 5-point scale (\\'no problems\\', \"slight problems\\', \"moderate problems\\', \"severe', \"problems', and 'extreme problems'). The second section consists of a vertical visual analogue\", 'scale anchored at 0 (\\'the worst health you can imagine\\') and 100 (\"the best health you can', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 73 of 169', \"imagine'). The EQ-5D-5L will be completed according to the SoP in Section 4. It will be\", 'completed electronically on the device supplied to the trial site and is included in the', 'investigator trial file.', '10.3.2.9 SF-36', 'The SF-36v2 (Acute Recall) is a 36-item general health status assessment. Subjects will be', 'asked to answer each question by selecting one of 3 to 6 categorical response options. The', 'instrument instructions do not state a specific recall period; however, a recall period is defined', 'within most items. The acute recall version, which asks subjects about the last week, will be', 'used in this trial (32).', 'The SF-36v2 (Acute Recall) yields scores for 8 health domains (physical functioning, role', 'physical, bodily pain, general health, vitality, social functioning, role emotional, and mental', 'health) and 2 psychometrically derived summary scores (a physical component summary and', 'a mental component summary).', 'The SF-36 will be completed according to the SoP in Section 4. It will be completed', 'electronically on the device supplied to the trial site and is included in the investigator trial', 'file.', '10.3.2.10 Work Productivity and Activity Impairment - General Health', \"The impact of AD on the subject's ability to work and perform regular activities will be\", 'assessed by Work Productivity and Activity Impairment - General Health (WPAI-GH). The', 'WPAI-GH questionnaire is an instrument to measure impairments in both paid work and', 'unpaid work (40). It consists of 6 items and measures absenteeism, presenteeism as well as', 'the impairments in unpaid activity because of health problem during the past 7 days. The', 'following 4 main outcomes can be generated from the WPAI-GH:', 'Percent work time missed due to health for those who were currently', 'employed.', 'Percent impairment while working due to health for those who were currently', 'employed and actually worked in the past 7 days.', 'Percent overall work impairment due to health for those who were currently', 'employed.', 'Percent activity impairment due to health for all respondents.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}